I n 1978, a study published in The Lancet reported 18 patients who had advanced chronic kidney disease (CKD), creatinine clearance of Ͻ35 ml/min, and presence of renal osteodystrophy and were treated with either vitamin D 3 (4000 IU/d) or 1,25-dihydroxyvitamin D [1,25(OH) 2 D; 1 g/d] along with 500 mg of calcium after a 6-mo observation period (1) . In the group treated with 1,25(OH) 2 D, seven of eight patients developed hypercalcemia that necessitated a reduction in dosage. The percentage fall in creatinine clearance was greater during treatment than before treatment in all patients who were on 1,25(OH) 2 D (P Ͻ 0.01) and in seven of nine patients on vitamin D 3 treatment (although the within group change here was NS). The authors concluded that deterioration of renal function was a major limitation of the clinical use of 1,25(OH) 2 D and vitamin D 3 in nondialyzed patients with CKD.
Although the conclusions made by this important clinical study were strong, evaluating the state-of-the-art science in 1978, Ͼ30 yr later informs us that the dosage of 1,25(OH) 2 D was rather high, the sample size too small, and the follow-up period of 6 mo too short to provide reliable information about the rates of progression of CKD in vitamin D-treated patients. Existing data seem to point to a salubrious effect of vitamin D receptor agonists (VDRA) in animals with kidney disease, and emerging evidence points to a similar benefit in patients with CKD. The evolution of science of VDRA in animal models of kidney disease and patients with CKD is the subject of this review.
The effects of vitamin D on the bone and elsewhere can be evaluated at the molecular level by examining knockout mice and are reviewed by Bouillon et al. (2) . Absence of a functional vitamin D receptor (VDR) or its ligand, 25-hydroxyvitamin D-1 [25(OH)D1] ␣-hydroxylase (CYP27B1), in mice creates a bone and growth plate phenotype that mimics severe vitamin D deficiency. VDR rescue in the intestine restores a normal bone and growth plate phenotype. Although the VDR is nearly ubiquitously expressed and almost all cells respond to 1,25(OH) 2 D exposure, the function of active vitamin D and its receptor is not fully overlapping. For example, VDR-deficient mice but not vitamin D-or 1 ␣-hydroxylase-deficient mice develop total alopecia as is also seen in humans. The immune system of VDR-or vitamin D-deficient mice shows increased sensitivity to autoimmune diseases such as inflammatory bowel disease or type 1 diabetes after exposure to predisposing factors. Although VDR-deficient mice do not have a spontaneous increase in cancer, they are more prone to oncogeneor chemocarcinogen-induced tumors. They also develop high renin hypertension, cardiac hypertrophy, and increased thrombogenicity. Vitamin D deficiency in humans is associated with increased prevalence of diseases, as predicted by the VDR null phenotype. Tian et al. (3) reviewed the mechanisms of salutary effects of vitamin D on the kidney. The noncalcemic effects of VDRA include vascular effects, immunomodulatory effects, anti-inflammatory effects, suppression of the renin-angiotensin system (RAS), and effects on glucose homeostasis, which are discussed further.
Animal Studies

Suppression of RAS
Seminal discoveries by Li et al. (4) demonstrated that vitamin D is a potent negative endocrine regulator of the RAS and works predominantly as a suppressor of renin biosynthesis (5) . Mice that lack the vitamin D receptor have elevated production of renin and angiotensin II (AngII), leading to hypertension, cardiac hypertrophy, and increased water intake. Vitamin D repression of renin expression is independent of calcium metabolism, the volume-and salt-sensing mechanisms, and the AngII feedback regulation (4) . In normal mice, vitamin D deficiency stimulates renin expression, whereas injection of 1,25(OH) 2 D reduces renin synthesis (4) . In cell cultures, 1,25(OH) 2 D directly suppresses renin gene transcription by a VDR-dependent mechanism. Combined treatment of diabetic mice with losartan and paricalcitol completely prevents albuminuria, restores glomerular filtration barrier structure, and markedly reduces glomerulosclerosis (6) . These beneficial effects are accompanied by blockade of intrarenal renin and AngII accumulation induced by hyperglycemia and losartan. These data demonstrate that inhibition of the RAS with combination of vitamin D analogs and RAS inhibitors effectively prevents renal injury in diabetic nephropathy. 1,25(OH) 2 D also suppresses hyperglycemia-induced activation of the RAS and TGF-␤ in mesangial and juxtaglomerular cells (7) . TGF-␤ activates interstitial fibroblasts and induces tubular epithelial-tomesenchymal transition. Thus, by blocking TGF-␤, VDRA have the potential to abrogate tubulointerstitial fibrosis. Taken together, these studies suggest that receptor-mediated vitamin D actions in part via the RAS may provide renoprotection in diabetic nephropathy.
Improvement in Insulin Resistance
Vitamin D deficiency has been linked with impaired glucose metabolism, an established risk factor for cardiovascular disease (8) . Because vitamin D is often deficient and its metabolism substantially impaired in patients with CKD, absolute or functional vitamin D deficiency may be particularly important in these patients. Furthermore, impaired glucose metabolism is common in CKD. De Boer (8) concluded in a recent review that short-term studies on maintenance hemodialysis patients have shown that vitamin D treatment improves insulin secretion and sensitivity, but interventional studies on people without ESRD have yielded mixed results. Improved glucose metabolism is one potential mechanism through which vitamin D may exert beneficial cardiovascular effects in patients with CKD, but further research is needed.
Vascular Effects
Somjen et al. (9) were the first to report an enzymatically active 25(OH)D1 ␣-hydroxylase system in human vascular smooth muscle cells, which could be upregulated by parathyroid hormone (PTH) and inhibited by exogenous vitamin D. Emerging experimental data demonstrate important physiologic effects of vitamin D on factors that are protective for vascular health (10) .
Immunomodulating Effects
Vitamin D seems to regulate innate immunity through effects on microbial recognition peptides such as Toll-like receptors (TLRs) (11) . TLRs are membrane-spanning receptors that recognize structurally conserved molecules derived from microbes and activate immune responses. Mycobacterium tuberculosis infection leads to increased 1 ␣-hydroxylase expression and VDR upregulation in monocyte/macrophages in response to activation by TLRs (12) . Furthermore, macrophages can also synthesize antimicrobial peptides such as cathelicidin, an effect that is facilitated in the presence of 25(OH)D (13) . In fact, it is now being recognized that autocrine production of 1,25(OH) 2 D might also be an important negative feedback mechanism to deactivate innate and inflammatory responses of activated macrophages (14) .
In the kidney, vitamin D has similar immunomodulating effects. For example, in vitro, 1,25(OH) 2 D attenuates TNF-␣-induced monocyte chemoattractant protein 1 (MCP-1) expression by human proximal tubule cells (15) . A synthetic VDRA, paricalcitol, inhibits renal inflammation by promoting VDRmediated sequestration of NF-B signaling (16) . Although cell surface receptor-mediated, nongenomic pathways (17,18) are described, the potent antiproliferative, prodifferentiative, and immunomodulating activities (17, 19, 20) seem to be modulated via vitamin D receptor-dependent genomic effects; the latter seem to provide the biologic basis for salutary effects of VDRA in patients with kidney disease.
Animal Models of Kidney Disease and Benefits of VDRA
Substantial number of studies point out the salutary effects of VDRA in animals ( Table 1 ). In aggregate there appears to be a consistent reduction in albuminuria, abrogation of glomerulosclerosis, glomerulomegaly and glomerular inflammation, effects that may be independent of BP and PTH. However, from these studies the effects of VDRA in preventing tubulointerstitial fibrosis and preventing the progression of kidney failure are less clear.
Human Studies
Vitamin D Deficiency in Patients with CKD
As renal function declines, serum levels of 1,25(OH) 2 D progressively decrease, leading to a vitamin D-deficient state (28) . Despite presence of adequate 25(OH)D, many patients with CKD will have low serum levels of 1,25(OH) 2 D, which underlies the functional vitamin D deficiency in these patients. Some- (30) . Whether similar benefits can be realized with vitamin D administration needs to be studied in future trials. Endothelial cells can also rapidly induce 1-␣ hydroxylase activity in response to inflammatory cytokines and may serve to deplete the stores of 25(OH)D (31) . In one small study, VDRA was unable to improve endothelial function, but a larger study with vitamin D is warranted. (35) reported that 25(OH)D as well as its active metabolite 1,25(OH) 2 D is directly associated with endothelial function and inversely with arterial calcifications in patients with CKD. Taken together, it seems that 25(OH)D deficiency in patients with CKD is associated with worse risk factors (albuminuria, insulin resistance, inflammation, hypertension, dyslipidemia, and endothelial dysfunction) for progression of kidney disease.
Vitamin D and Cohort Studies in CKD
The presence of vitamin D deficiency is associated with incident cardiovascular disease in the general population (36) . Because risk factors for cardiovascular and kidney disease by and large overlap, it is possible that cardiovascular and renal benefits may accrue in patients with CKD. In fact, several studies of patients who had CKD and were not on dialysis supported the presence of a salutary effect of vitamin D. In an Italian cohort, Ravani et al. (37) found that 25(OH)D plasma concentration was an independent inverse predictor of disease progression and death in patients with stages 2 through 5 CKD after multivariate adjustment. Shoben et al. (38) reported that oral calcitriol use was associated with lower mortality in nondialysis US veterans with CKD. After multivariate adjustment including eGFR and baseline levels of PTH, calcium, and phosphorous, oral calcitriol use was associated with a 26% lower risk for death and a 20% lower risk for death or dialysis. The association of calcitriol with improved survival was not statistically different across baseline PTH levels, although calcitriol use was associated with a greater risk for hypercalcemia. In another cohort of US veterans with CKD, Kovesdy et al. (39) reported that the incidence rate ratios for mortality and combined death and dialysis initiation were significantly lower in patients who were treated with calcitriol. Treatment with calcitriol was also associated with a trend toward a lower incidence of dialysis.
It remains that neither cross-sectional nor longitudinal studies can prove a cause-and-effect relationship between use of VDRA and outcomes. Randomized trials are needed.
Randomized Trials of VDRA in Patients with CKD
At least three clinical trials have evaluated the use of VDRA in patients who had CKD and were not on renal replacement therapy. In the first study, Agarwal et al. (40) reported reduction in proteinuria detected semiquantitatively by dipstick using an automated analysis in patients who had stages 3 and 4 CKD with secondary hyperparathyroidism and participated in three randomized, controlled trials of oral paricalcitol. In that post hoc analysis, reduction in dipstick proteinuria occurred in the face of the frequent use of agents that block the RAS. Although previous studies reported that dipstick proteinuria is a good predictor of spot urine protein/creatinine ratios, an obvious limitation of that study was the method of detection of proteinuria (automated dipstick versus spot urinary protein/ creatinine or albumin/creatinine ratio).
Extending these findings, Alborzi et al. (30) reported a prospective pilot trial of 24 patients who had CKD (two patients stage 2, remaining stage 3) and were randomly allocated in a double-blind manner to three equal groups to receive 0, 1, or 2 g of paricalcitol, a vitamin D analog, orally for 1 mo. At 1 mo, treatment/baseline ratio of high-sensitivity C-reactive protein was 1.5 (95% confidence interval [CI] 1.1 to 2.1; P ϭ 0.02) with placebo, 0.8 (95% CI 0.3 to 1.9; P ϭ 0.62) with 1-g dosage, and 0.5 (95% CI 0.3 to 0.9; P ϭ 0. 03) with 2-g dosage of paricalcitol. At 1 mo, treatment/baseline ratio of 24-h albumin excretion rate was 1.35 (95% CI 1.08 to 1.69; P ϭ 0.01) with placebo, 0.52 (95% CI 0.40 to 0.69; P Ͻ 0.001) with 1-g dosage, and 0.54 (95% CI 0.35 to 0.83; P ϭ 0. 01) with 2-g dosage (P Ͻ 0.001 for between-group changes). No differences were observed in iothalamate clearance, flow-mediated dilation (a measure of endothelial function), 24-h ambulatory BP, or PTH with treatment or upon washout. The limitations of that trial include the small sample size and the limited duration of exposure to VDR activator. Furthermore, all patients had low 25(OH)D deficiency in that study; whether nutritional replacement could have improved albuminuria or inflammation remains unknown. That study therefore cannot provide definite answers to questions of the clinical use of paricalcitol for renal protection; however, it seems from that study that paricalcitol-induced reduction in albuminuria and inflammation may be mediated independent of its effects on hemodynamics or PTH suppression.
In an uncontrolled trial, reported from Hong Kong, 10 patients with biopsy-proven IgA nephropathy and persistent proteinuria despite angiotensin-converting enzyme inhibition and AngII receptor blockade were treated with 0.5 g calcitriol twice weekly for 12 wk (41). After calcitriol treatment, there was a significant overall decrease in urine protein-creatinine ratio from 1.98 Ϯ 0.74 to 1.48 Ϯ 0.81 g/g (P ϭ 0.007) during the first 6 wk that persisted throughout the study period. No significant change in BP or renal function was noted. There was a simultaneous decrease in serum TGF-␤ level, and percentage of decrease in serum TGF-␤ level significantly correlated with percentage of change in proteinuria (Spearman r ϭ 0.643; P ϭ 0.02).
Whether VDRA should be used to reduce the rate of progression of CKD cannot be answered by the studies discussed herein; larger trials are required. Lowering of albuminuria or proteinuria in these trials, however, occurred without changes in BP even when recorded by ambulatory BP monitoring, raising the notion that improvement in kidney disease conferred by the use of these drugs may occur via nonhemodynamic pathways.
Future Directions
Randomized, controlled trials with paricalcitol are under way to demonstrate whether paricalcitol will have antiproteinuric or cardioprotective effects in patients with CKD. In one such trial, reduction in albuminuria from baseline to 24 wk is the primary end point (ClinicalTrials.gov identifier NCT00421733), whereas, in another, the change in left ventricular mass index assessed by cardiac magnetic resonance imaging over 48 wk is the primary end point (ClinicalTrials.gov identifier NCT00497146). The Vitamin D Receptor Activator (Paricalcitol) in Albuminuria Lowering (VITAL) study has randomly assigned 282 patients with diabetes in a double-blind, multicenter trial to placebo or 1 or 2 g of paricalcitol taken once daily in patients with eGFR between 15 and 90 ml/min per 1.73 m 2 and urine albumin/creatinine concentration between 100 and 3000 mg/d on average of three morning void specimen. All patients have to be on a stable dosage of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker and have reasonable control of BP and blood glucose to participate. Results are awaited. Each of these trials, conducted with patients with CKD, should provide better evidence (or lack thereof) for cardiovascular and renal protection.
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